Apixaban is an oral direct Factor Xa inhibitor belonging to the class of novel oral anticoagulants (NOACs). It offers predictable anticoagulant activity with a wide therapeutic window and does not require routine coagulation monitoring, making it a preferred alternative to warfarin in eligible patients. Indicated for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent VTE, and thromboprophylaxis following elective hip or knee replacement surgery.